Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib
- PMID: 35934607
- DOI: 10.1016/j.ejca.2022.06.039
Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib
Conflict of interest statement
Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: P.B. reports honoraria from AstraZeneca, Bayer, Biocartis, Janssen, Novartis and ThermoFisher outside of the submitted work. A.F. reports honoraria from Biocartis outside of the submitted work. G.G. reports honoraria from Eli Lilly and Merck outside of the submitted work. K.T. reports honoraria from Roche outside of the submitted work. P.T. reports honoraria from AstraZeneca, Bayer, Janssen, Novartis, Pfizer, Roche, MSD, BMS, Agilent, Ventana and Guardant outside of the submitted work. Others declare no potential conflicts of interest.
Comment in
-
Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib': Not looking back.Eur J Cancer. 2022 Oct;174:318-320. doi: 10.1016/j.ejca.2022.06.040. Epub 2022 Aug 7. Eur J Cancer. 2022. PMID: 35948502 No abstract available.
Comment on
-
Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib.Eur J Cancer. 2022 May;166:38-40. doi: 10.1016/j.ejca.2022.02.007. Epub 2022 Mar 8. Eur J Cancer. 2022. PMID: 35276501 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources